Preclinical

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Esther Redin, Irati Garmendia, Teresa Lozano, Diego Serrano, Yaiza Senent, Miriam Redrado, Maria Villalba, Carlos E De Andrea, Francisco Exposito, Daniel Ajona, Sergio Ortiz-Espinosa, Ana Remirez, Cristina Bertolo, Cristina Sainz, Juana Garcia-Pedrero, Ruben Pio, Juan Lasarte, Jackeline Agorreta, Luis M Montuenga, Alfonso Calvo

Journal for ImmunoTherapy of Cancer Mar 2021, 9 (3) e001496; DOI: 10.1136/jitc-2020-001496
TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism
Stefania Canè, Jacques Van Snick, Catherine Uyttenhove, Luc Pilotte, Benoit J Van den Eynde

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e001798; DOI: 10.1136/jitc-2020-001798
In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
Adrianne L Jenner, Tyler Cassidy, Katia Belaid, Marie-Claude Bourgeois-Daigneault, Morgan Craig

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e001387; DOI: 10.1136/jitc-2020-001387
Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy
Nina M. Muñoz, Malea Williams, Katherine Dixon, Crystal Dupuis, Amanda McWatters, Rony Avritscher, Soraya Zorro Manrique, Kevin McHugh, Ravi Murthy, Alda Tam, Aung Naing, Sapna P. Patel, David Leach, Jeffrey D. Hartgerink, Simon Young, Punit Prakash, Patrick Hwu, Rahul A. Sheth

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e001800; DOI: 10.1136/jitc-2020-001800
Letter to the editor: Checking the pulse of adoptive cell therapy for solid tumors. Thoughts from the abstracts submitted to the 35th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2020)
Martina Markovska, Francesco Marincola

Journal for ImmunoTherapy of Cancer Jan 2021, 9 (1) e002216; DOI: 10.1136/jitc-2020-002216
Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes
Javier Arranz-Nicolás, Miguel Martin-Salgado, Cristina Rodríguez-Rodríguez, Rosa Liébana, Maria C Moreno-Ortiz, Judith Leitner, Peter Steinberger, Antonia Ávila-Flores, Isabel Merida

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (2) e001521; DOI: 10.1136/jitc-2020-001521
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
Anne Y Lai, Jessica A Sorrentino, Konstantin H Dragnev, Jared M Weiss, Taofeek K Owonikoko, Julie A Rytlewski, Jill Hood, Zhao Yang, Rajesh K Malik, Jay C Strum, Patrick J Roberts

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e000847; DOI: 10.1136/jitc-2020-000847
Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B
Ana Alvarez de Cienfuegos, Lawrence H Cheung, Khalid A Mohamedali, Timothy G Whitsett, Jeffrey A Winkles, Walter N Hittelman, Michael G Rosenblum

Journal for ImmunoTherapy of Cancer Sep 2020, 8 (2) e001138; DOI: 10.1136/jitc-2020-001138
Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells
Inez Johanna, Trudy Straetemans, Sabine Heijhuurs, Tineke Aarts-Riemens, Håkan Norell, Laura Bongiovanni, Alain de Bruin, Zsolt Sebestyen, Jürgen Kuball

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 69; DOI: 10.1186/s40425-019-0558-4
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew E. Hendifar, Richard Tuli

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 46; DOI: 10.1186/s40425-018-0361-7

Log in using your username and password

Main menu

Log in using your username and password

You are here

Preclinical